{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:42:19Z","timestamp":1789051339233,"version":"build-2803163510"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Nutmeg (Myristica fragrans) has been traditionally used in herbal medicine, but its potential anti-cancer effects remain largely unexplored. This study aimed to investigate the molecular mechanisms of nutmeg against bladder cancer through an integrated strategy combining network pharmacology, molecular docking, and\n                      <jats:italic>in vitro<\/jats:italic>\n                      validation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Active compounds of nutmeg were retrieved from the TCMSP and PubChem databases using oral bioavailability (OB \u226530%) and drug-likeness (DL \u22650.18) as criteria. Potential targets were predicted using SwissTargetPrediction and cross-referenced with bladder cancer-related genes from GeneCards, OMIM, and TTD. Common targets were analyzed by STRING, Cytoscape, and DAVID for PPI, GO, and KEGG enrichment. Molecular docking was performed to evaluate binding affinities between candidate compounds and core targets.\n                      <jats:italic>In vitro<\/jats:italic>\n                      experiments, including CCK-8, colony formation, wound-healing, Transwell, flow cytometry, and Western blotting, were conducted to validate the anti-tumor effects of \u03b2-sitosterol on T24 and 5637 bladder cancer cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nine active compounds were identified, with \u03b2-sitosterol emerging as the key candidate. A total of 284 overlapping targets were obtained between nutmeg and bladder cancer. GO and KEGG enrichment suggested significant involvement in apoptosis and PI3K-Akt signaling pathways. Molecular docking showed that \u03b2-sitosterol exhibited strong binding to BCL-2 (\u20138.6 kcal\/mol) and CASP3 (\u20138.3 kcal\/mol).\n                      <jats:italic>In vitro<\/jats:italic>\n                      , \u03b2-sitosterol significantly reduced cell viability (IC\n                      <jats:sub>50<\/jats:sub>\n                      : 50 \u03bcM for 5637, 60 \u03bcM for T24), inhibited proliferation, colony formation, and migration, and induced apoptosis in a dose-dependent manner. Western blot confirmed upregulation of Bax and cleaved Caspase-3 and downregulation of BCL-2.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrates that \u03b2-sitosterol, a major bioactive compound of nutmeg, suppresses bladder cancer progression by modulating the BCL-2\/Bax\/Caspase-3 axis and PI3K-Akt signaling pathway. These findings provide novel insights into the therapeutic potential of nutmeg as a complementary strategy for bladder cancer treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1698721","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:21:48Z","timestamp":1762147308000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Mechanism of active component \u03b2-sitosterol from Myristica fragrans inducing apoptosis in bladder cancer cells via regulating the BCL-2\/BAX\/caspase-3 pathway"],"prefix":"10.3389","volume":"15","author":[{"given":"Yongkang","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyue","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haozhe","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-02984-4","article-title":"The global burden of urinary bladder cancer: an update","volume":"38","author":"Richters","year":"2020","journal-title":"World J Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of bladder cancer in 2023: A systematic review of risk factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"954","DOI":"10.3390\/ijerph21070954","article-title":"Risk factors associated with urothelial bladder cancer","volume":"21","author":"Alouini","year":"2024","journal-title":"Int J Environ Res Public Health"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00578-1","article-title":"Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective","volume":"19","author":"Teoh","year":"2022","journal-title":"Nat Rev Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acc.2021.07.005","article-title":"Biomarkers in muscle invasive bladder cancer","volume":"107","author":"Wilson","year":"2022","journal-title":"Adv Clin Chem"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/med4.27","article-title":"Crosstalk between cancer cells and the nervous system","volume":"1","author":"Huang","year":"2023","journal-title":"Med Adv"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e20250016","DOI":"10.1002\/INMD.20250016","article-title":"Patient-derived xenograft models in pan-cancer: From bench to clinic","volume":"3","author":"Li","year":"2025","journal-title":"Interdiscip Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.20517\/cdr.2024.97","article-title":"The role and clinical applications of exosomes in cancer drug resistance","volume":"7","author":"Pan","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.03.024","article-title":"A comprehensive review of integrative pharmacology-based investigation: A paradigm shift in traditional Chinese medicine","volume":"11","author":"Xu","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7576818","article-title":"Anti-Helicobacter pylori, Anti-Inflammatory, Cytotoxic, and Antioxidant Activities of Mace Extracts from Myristica fragrans","volume":"2020","author":"Suthisamphat","year":"2020","journal-title":"Evid Based Complement Alternat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12011-012-9443-4","article-title":"Estimation of trace elements in mace (Myristica fragrans Houtt) and their effect on uterine cervix cancer induced by methylcholanthrene","volume":"149","author":"Zhang","year":"2012","journal-title":"Biol Trace Elem Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13020-019-0270-9","article-title":"Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine","volume":"14","author":"Luo","year":"2019","journal-title":"Chin Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaf078","article-title":"NP-TCMtarget: a network pharmacology platform for exploring mechanisms of action of traditional Chinese medicine","volume":"26","author":"Wang","year":"2024","journal-title":"Brief Bioinform"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.7491","article-title":"Nutmeg (Myristica fragrans Houtt.) essential oil: A review on its composition, biological, and pharmacological activities","volume":"36","author":"Ashokkumar","year":"2022","journal-title":"Phytother Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"18321","DOI":"10.1038\/s41598-024-68844-3","article-title":"Predicting prognosis and drug sensitivity in bladder cancer: an insight into Pan-programmed cell death patterns regulated by M6A modifications","volume":"14","author":"Wang","year":"2024","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02331","article-title":"Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline","volume":"41","author":"Shah","year":"2023","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2016.08.033","article-title":"Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance","volume":"64","author":"Zhai","year":"2017","journal-title":"Semin Cell Dev Biol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.3390\/ijms25063178","article-title":"PI3K\/akt\/mTOR signaling pathway as a target for colorectal cancer treatment","volume":"25","author":"Leiphrakpam","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3390\/cancers11101480","article-title":"Epigenetic mechanisms of escape from BRAF oncogene dependency","volume":"11","author":"Khaliq","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.3390\/ijms23042144","article-title":"Curcumin as an enhancer of therapeutic efficiency of chemotherapy drugs in breast cancer","volume":"23","author":"Farghadani","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00123","article-title":"Network pharmacology databases for traditional chinese medicine: review and assessment","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2025.119479","article-title":"Huachansu suppresses colorectal cancer via inhibiting PI3K\/AKT and glycolysis signaling pathways: Systems biology and network pharmacology","volume":"343","author":"Yang","year":"2025","journal-title":"J Ethnopharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13020-023-00853-2","article-title":"Network pharmacology: a bright guiding light on the way to explore the personalized precise medication of traditional Chinese medicine","volume":"18","author":"Li","year":"2023","journal-title":"Chin Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-020-0270-8","article-title":"Emerging connectivity of programmed cell death pathways and its physiological implications","volume":"21","author":"Bedoui","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e34871","DOI":"10.1097\/MD.0000000000034871","article-title":"Network pharmacology to explore the molecular mechanisms of Prunella vulgaris for treating thyroid cancer","volume":"102","author":"Zhang","year":"2023","journal-title":"Med (Baltimore)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0263614","DOI":"10.1371\/journal.pone.0263614","article-title":"A network pharmacology approach to explore active compounds and pharmacological mechanisms of a patented Chinese herbal medicine in the treatment of endometriosis","volume":"17","author":"Wu","year":"2022","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41571-018-0026-y","article-title":"Treatment resistance in urothelial carcinoma: an evolutionary perspective","volume":"15","author":"Vlachostergios","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e19332","DOI":"10.7717\/peerj.19332","article-title":"Research progress of nano drug delivery systems in the anti-tumor treatment of traditional Chinese medicine monomers","volume":"13","author":"Song","year":"2025","journal-title":"PeerJ"},{"key":"B32","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1142\/S0192415X24500253","article-title":"Traditional chinese medicine for cancer treatment","volume":"52","author":"Liu","year":"2024","journal-title":"Am J Chin Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.03.004","article-title":"Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-020-01285-4","article-title":"Phytochemical and pharmacological properties of Myristica fragrans Houtt","volume":"43","author":"Ha","year":"2020","journal-title":"an updated review. Arch Pharm Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.dib.2020.105997","article-title":"Lignan compound isolated from n-Hexane extract myristica fragrans Houtt root as antioxidant and antitumor activities against MCF-7 cell lines data","volume":"31","author":"Ginting","year":"2020","journal-title":"Data Brief"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-023-00629-4","article-title":"cMechanisms of BCL-2 family proteins in mitochondrial apoptosis","volume":"24","author":"Czabotar","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X20666220327222921","article-title":"Inhibition of caspase 3 and caspase 9 mediated apoptosis: A multimodal therapeutic target in traumatic brain injury","volume":"21","author":"Unnisa","year":"2023","journal-title":"Curr Neuropharmacol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2021.153601","article-title":"Resveratrol inhibits MUC5AC expression by regulating SPDEF in lung cancer cells","volume":"89","author":"Lin","year":"2021","journal-title":"Phytomedicine"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3727\/096504018X15149787144385","article-title":"miR-202 inhibits cell proliferation, migration, and invasion by targeting epidermal growth factor receptor in human bladder cancer","volume":"26","author":"Zhang","year":"2018","journal-title":"Oncol Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.advnut.2023.05.013","article-title":"\u03b2-Sitosterol as a Promising Anticancer Agent for Chemoprevention and Chemotherapy: Mechanisms of Action and Future Prospects","volume":"14","author":"Wang","year":"2023","journal-title":"Adv Nutr"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.62347\/NZCG1179","article-title":"\u03b2-sitosterol suppresses fibroblast growth factor and epidermal growth factor receptors to induce apoptosis and inhibit migration in lung cancer: an in vitro study","volume":"15","author":"Kan","year":"2025","journal-title":"Am J Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1698721\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:21:48Z","timestamp":1762147308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1698721\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":42,"alternative-id":["10.3389\/fonc.2025.1698721"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1698721","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"article-number":"1698721"}}